GlassScriptPhysician profile
Michael J Willis
NPI 1780032706
$3,047.85
in general payments reported to CMS, 2019-2025
14 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $32.66 · 2021: $17.87 · 2022: $533 · 2023: $560 · 2024: $521 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $1,067.28 | 2019-2024 | Physio-Stim, Accelstim |
| Organogenesis INC. | $822.02 | 2022-2025 | Affinity, Affinity, Puraply |
| Triad Life Sciences INC. | $258.58 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $236.27 | 2022-2025 | Nuzyra |
| Medtronic, INC. | $172.47 | 2024 | Intellis Adaptivestim |
| Smith+Nephew, INC. | $171.77 | 2023-2025 | Grafix Pl, Stravix Pl, Collagenase Santyl |
| Abbvie INC. | $128.04 | 2023 | Dalvance |
| Amgen INC. | $74.23 | 2024 | Krystexxa |
| Averitas Pharma INC. | $30.81 | 2024-2025 | Qutenza |
| Fusion Orthopedics USA, LLC | $22.01 | 2025 | |
| Bard Peripheral Vascular, INC. | $20.94 | 2020 | |
| Convatec INC. | $17.28 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.43 | 2022 | |
| Biodelivery Sciences International, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.